keyword
MENU ▼
Read by QxMD icon Read
search

Acute myeloid leukemia

keyword
https://www.readbyqxmd.com/read/29036962/-cladribine-in-the-treatment-of-tet2-refractory-acute-myeloid-leukemia-a-case-report
#1
J Liu, R Guo, Z X Jiang
No abstract text is available yet for this article.
October 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29035575/hetfhmm-a-novel-approach-to-infer-tumor-heterogeneity-using-factorial-hidden-markov-models
#2
Mohammad S Rahman, Ann E Nicholson, Gholamreza Haffari
Cancer arises from successive rounds of mutations, resulting in tumor cells with different somatic mutations known as clones. Drug responsiveness and therapeutics of cancer depend on the accurate detection of clones in a tumor sample. Recent research has considered inferring clonal composition of a tumor sample using computational models based on short read data of the sample generated using next-generation sequencing (NGS) technology. Short reads (segmented DNA parts of different tumor cells) are noisy; therefore, inferring the clones and their mutations from the data is a difficult and complex problem...
October 16, 2017: Journal of Computational Biology: a Journal of Computational Molecular Cell Biology
https://www.readbyqxmd.com/read/29035445/expression-of-leukocytic-syncytin-1-in-b-cell-acute-lymphoblastic-leukemia-and-acute-myeloid-leukemia-patients
#3
Yi Sun, Hongyan Zhu, Jianxin Song, Yaxian Jiang, Hongmei Ouyang, Ting Dong, Rui Tao, Xin Fan, Guiqian Zhang
BACKGROUND: Syncytin-1 is improperly expressed in several cancers. However, its expression profile across leukocytes in leukemia patients has not yet been analyzed. METHODS: A total of 50 AML cases and 14 B-cell ALL patients were consecutively recruited. Bone marrow samples were subjected to flow cytometry. Statistical analysis was applied to compare syncytin-1 expression between B-cell ALL and AML across granulocytes, leukemia cells, and T-lymphocytes (including CD3+, CD4+, and CD8+ subsets thereof) and to correlate syncytin-1 expression to leukemia cells and lymphocytes with the T-cell subset percentages...
October 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29035192/bacillus-cereus-bacteremia-with-central-nervous-system-involvement-a-neuropathological-study
#4
Jean Philippe Brouland, Nathalie Sala, Selin Tusgul, Caterina Rebecchini, Enikö Kovari
Bacillus cereus is a widely-distributed, gram-positive or variable, rod-shaped bacterium frequently considered a contaminant in clinical specimens. It is recognized as a potential pathogen inducing self-limiting emetic or diarrheal food poisoning or localized infection in immunocompetent patients. True B. cereus bacteremia is uncommon and mainly observed in fragile patients, notably in immunocompromised individuals. We report clinical, radiological, and pathological findings of a 64-year-old patient with a history of acute myeloid leukemia who initially presented a fever while neutropenic after the induction of a second cycle of chemotherapy...
October 16, 2017: Clinical Neuropathology
https://www.readbyqxmd.com/read/29034885/generation-and-characterization-of-a-human-induced-pluripotent-stem-ips-cell-line-derived-from-an-acute-myeloid-leukemia-patient-evolving-from-primary-myelofibrosis-carrying-the-calr-52bp-deletion-and-the-asxl1-p-r693x-mutation
#5
Cintia E Gomez Limia, Sylvie Devalle, Marcelo Reis, Jaroslaw Sochacki, Mayra Carneiro, Rodrigo Madeiro da Costa, Mariana D'Andrea, Telma Padilha, Ilana R Zalcberg, Cristiana Solza, Adelmo Daumas, Stevens Rehen, Bárbara Monte-Mór, Martín H Bonamino
Peripheral blood sample was donated by a 61years old female patient diagnosed with acute myeloid leukemia secondary to a primary myelofibrosis harboring the 52-bp deletion in the CALR gene (c.1092_1143del, p.L367fs*46) and the R693X mutation in the ASXL1 gene (c.2077C>T, p.R693X). CD34+ cells were isolated from the sample and subjected to the reprogramming procedure by using the Sendai virus carrying the reprogramming factors Oct3/4, Sox2, Klf4 and c-Myc. iPS colonies generated retained the original mutations and displayed all the features of bona fide iPS cells...
October 2017: Stem Cell Research
https://www.readbyqxmd.com/read/29034366/a-phase-2-study-incorporating-sorafenib-into-the-chemotherapy-for-older-adults-with-flt3-mutated-acute-myeloid-leukemia-calgb-11001
#6
Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J Levis, Heidi D Klepin, Maria R Baer, Bayard L Powell, Peter Westervelt, Daniel J DeAngelo, Wendy Stock, Ben Sanford, William G Blum, Clara D Bloomfield, Richard M Stone, Richard A Larson
The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). In this study, sorafenib was added to daunorubicin and cytarabine-based induction and consolidation chemotherapy and was also continued for 12 months of maintenance therapy. The primary end point of the study was overall survival (OS) at 1 year in the FLT3 internal tandem duplication (FLT3-ITD) cohort...
January 24, 2017: Blood Advances
https://www.readbyqxmd.com/read/29034209/bridge-induced-translocation-between-nup145-and-top2-yeast-genes-models-the-genetic-fusion-between-the-human-orthologs-associated-with-acute-myeloid-leukemia
#7
Valentina Tosato, Nicole West, Jan Zrimec, Dmitri V Nikitin, Giannino Del Sal, Roberto Marano, Michael Breitenbach, Carlo V Bruschi
In mammalian organisms liquid tumors such as acute myeloid leukemia (AML) are related to spontaneous chromosomal translocations ensuing in gene fusions. We previously developed a system named bridge-induced translocation (BIT) that allows linking together two different chromosomes exploiting the strong endogenous homologous recombination system of the yeast Saccharomyces cerevisiae. The BIT system generates a heterogeneous population of cells with different aneuploidies and severe aberrant phenotypes reminiscent of a cancerogenic transformation...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29034206/leukemia-initiating-cells-in-t-cell-acute-lymphoblastic-leukemia
#8
REVIEW
Shi Hao Tan, Fatima Carla Bertulfo, Takaomi Sanda
T-cell acute lymphoblastic leukemia (T-ALL) is a hematological malignancy characterized by the clonal proliferation of immature T-cell precursors. T-ALL has many similar pathophysiological features to acute myeloid leukemia, which has been extensively studied in the establishment of the cancer stem cell (CSC) theory, but the CSC concept in T-ALL is still debatable. Although leukemia-initiating cells (LICs), which can generate leukemia in a xenograft setting, have been found in both human T-ALL patients and animal models, the nature and origin of LICs are largely unknown...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29033820/pachyderma-in-primary-cutaneous-nk-and-t-cell-lymphoma-and-leukemia-cutis
#9
Eve Lebas, Cesar Chian, Nazli Nikkels-Tassoudji, Jorge E Arrese, Arjen F Nikkels
BACKGROUND: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC). AIM: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma. RESULTS: In a series of pCNKTCL (n = 70), pCBCL (n = 12), and LC (n = 2) patients followed up during 9 years, 6 cases of pachyderma were observed...
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29032147/high-bone-marrow-mir-19b-level-predicts-poor-prognosis-and-disease-recurrence-in-de-novo-acute-myeloid-leukemia
#10
Ting-Juan Zhang, Jiang Lin, Jing-Dong Zhou, Xi-Xi Li, Wei Zhang, Hong Guo, Zi-Jun Xu, Yang Yan, Ji-Chun Ma, Jun Qian
Oncogenic role of miR-19 family has been identified in human cancers especially in lymphoid malignancies. However, to date, little studies investigated the role of miR-19 family in myeloid malignancies. Herein, we examined miR-19a/b expression and explored its clinical significance in de novo acute myeloid leukemia (AML). The detection of miR-19a/b expression was performed by real-time quantitative PCR in bone marrow mononuclear cells of 113 patients and 42 healthy donors. Both miR-19a/b levels were significantly increased in AML patients in contrast to controls...
October 12, 2017: Gene
https://www.readbyqxmd.com/read/29030092/a-phase-ii-study-of-clag-regimen-combined-with-imatinib-mesylate-for-relapsed-or-refractory-acute-myeloid-leukemia
#11
Abu-Sayeef Mirza, Jeffrey E Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F List, Rami S Komrokji
INTRODUCTION: No standard salvage chemotherapy regimen is available for relapsed or refractory (RR) acute myeloid leukemia (AML). Preclinical data have suggested synergy in vitro between cytarabine and imatinib mesylate (IM) on AML cell growth inhibition. After demonstrating the safety and feasibility in a phase I study, we conducted a phase II clinical study of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor) regimen combined with IM for patients with RR-AML. PATIENTS AND METHODS: We performed a single-institution 2-stage phase II study...
September 19, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29029494/kras-overexpression-independent-of-ras-mutations-confers-an-adverse-prognosis-in-cytogenetically-normal-acute-myeloid-leukemia
#12
Jing-Dong Zhou, Dong-Ming Yao, Xi-Xi Li, Ting-Juan Zhang, Wei Zhang, Ji-Chun Ma, Hong Guo, Zhao-Qun Deng, Jiang Lin, Jun Qian
The prognostic value of RAS mutations has been systematically investigated in acute myeloid leukemia (AML). However, clinical significance of RAS expressions in AML remains poorly determined. To explore the clinical significance, we analyzed KRAS and NRAS expressions in 143 de novo AML patients by real-time quantitative PCR. KRAS and NRAS expressions were significantly up-regulated in AML patients. KRAS and NRAS mutations were identified in 4% (6/143) and 8% (12/143) of these patients, respectively. However, no significant association was observed between RAS mutations and expressions...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029424/microrna-22-can-regulate-expression-of-the-long-non-coding-rna-meg3-in-acute-myeloid-leukemia
#13
Hongxia Yao, Pei Sun, Mengling Duan, Lie Lin, Yanping Pan, Congming Wu, Xiangjun Fu, Hua Wang, Li Guo, Tianbo Jin, Yipeng Ding
AIM: Acute myeloid leukemia (AML) is the most common blood tumor with poor prognosis. At present, the research found that the pathogenesis of AML is related to many factors, such as recurrent somatic mutations and gene expression and epigenetic changes, however, the molecular mechanism of AML is still unclear. Long non-coding RNA MEG3 is a newly found tumor suppressor and plays a very important role in the regulation of a variety of tumor formation and progression. Studies found that the MEG3 expression was significantly decreased in AML...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29028392/application-of-selected-reaction-monitoring-and-parallel-reaction-monitoring-for-investigation-of-hl-60-cell-line-differentiation
#14
Svetlana E Novikova, Olga V Tikhonova, Leonid K Kurbatov, Tatiana E Farafonova, Igor V Vakhrushev, Victor G Zgoda
Targeted mass spectrometry represents a powerful tool for investigation of biological processes. The convenient approach of selected reaction monitoring using stable isotope-labeled peptide standard (SIS) is widely applied for protein quantification. Along with this method, high-resolution parallel reaction monitoring has been increasingly used for protein targeted analysis. Here we applied two targeted approaches (selected reaction monitoring with SIS and label-free parallel reaction monitoring) to investigate expression of 11 proteins during all-trans retinoic acid-induced differentiation of HL-60 cells...
August 2017: European Journal of Mass Spectrometry
https://www.readbyqxmd.com/read/29027647/dasatinib-associated-reversible-demyelinating-peripheral-polyneuropathy-in-a-case-of-chronic-myeloid-leukemia
#15
Takashi Ishida, Naoyuki Akagawa, Tomomi Miyata, Naomi Tominaga, Takahiro Iizuka, Masaaki Higashihara, Takahiro Suzuki, Koji Miyazaki
Tyrosine kinase inhibitors (TKIs) are essential for the treatment of chronic myeloid leukemia (CML). Adverse effects of dasatinib have been reported; however, few reports have highlighted the association between dasatinib and demyelinating peripheral neuropathy (DPN). We report a patient with CML who developed acute onset of DPN associated with dasatinib therapy. A 46-year-old Japanese woman was treated with dasatinib for 7 months after the diagnosis of CML and she achieved a major molecular response (MMR)...
October 13, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29027628/the-prognostic-significance-of-measurable-minimal-residual-disease-in-acute-myeloid-leukemia
#16
REVIEW
Francesco Buccisano, Christopher S Hourigan, Roland B Walter
PURPOSE OF REVIEW: The purpose of this review was to evaluate recent literature on detection methodologies for, and prognostic significance of, measurable ("minimal") residual disease (MRD) in acute myeloid leukemia (AML). RECENT FINDINGS: There is no "one-fits-all" approach to MRD testing in AML. Most exploited to date are methods relying on immunophenotypic aberrancies (identified via multiparameter flow cytometry) or genetic abnormalities (identified via PCR-based assays)...
October 13, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29027108/prognostic-value-of-genetic-mutations-in-adolescent-and-young-adults-with-acute-myeloid-leukemia
#17
Yachiyo Kuwatsuka, Daisuke Tomizawa, Rika Kihara, Yasunobu Nagata, Norio Shiba, Yuka Iijima-Yamashita, Akira Shimada, Takao Deguchi, Hayato Miyachi, Akio Tawa, Takashi Taga, Akitoshi Kinoshita, Hideki Nakayama, Nobutaka Kiyokawa, Akiko Moriya Saito, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Norio Asou, Shigeki Ohtake, Shuichi Miyawaki, Yasushi Miyazaki, Toru Sakura, Yukiyasu Ozawa, Noriko Usui, Heiwa Kanamori, Yoshikazu Ito, Kiyotoshi Imai, Youko Suehiro, Shinichi Kobayashi, Kunio Kitamura, Emiko Sakaida, Seishi Ogawa, Tomoki Naoe, Yasuhide Hayashi, Keizo Horibe, Atsushi Manabe, Shuki Mizutani, Souichi Adachi, Hitoshi Kiyoi
Clinical outcomes and the genetic background of acute myeloid leukemia (AML) in adolescent and young adults (AYAs) are known to differ in younger children and older adults. To clarify the impact of genetic mutations on clinical outcomes of AYAs with AML, we analyzed data from the JPLSG AML-05 and JALSG AML201 studies. AYAs aged 15-39 years (n = 103) were included. FLT3-ITD, KIT, CEBPA, NRAS, KRAS, WT1, MLL-PTD, and NPM1 mutations were analyzed. Overall survival (OS) of the AYAs was 61% and event-free survival was 38% at 3 years...
October 12, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29026839/missing-the-benefit-of-metformin-in-acute-myeloid-leukemia-a-problem-of-contrast
#18
Alice C Ceacareanu, George K Nimako, Zachary A P Wintrob
OBJECTIVE: To evaluate whether metformin's cancer-related benefits reported in patients with solid tumors (ST) are also present in acute myeloid leukemia (AML) patients. METHODS: Baseline demographic and clinical history for all diabetes mellitus patients newly diagnosed with AML or cancer of the breast, ovary, prostate, gastrointestinal tract, lung, or kidney at Roswell Park Cancer Institute in Buffalo, NY (January 2003-December 2010, n = 924) was collected. Overall survival (OS) and disease-free survival (DFS) were assessed by Kaplan-Meier (KM) analysis and Cox proportional hazards regression (hazard ratio [HR])...
July 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29026712/therapy-related-acute-myeloid-leukemia-following-treatment-for-burkitt-s-lymphoma
#19
Seung-Shin Lee
No abstract text is available yet for this article.
September 2017: Chonnam Medical Journal
https://www.readbyqxmd.com/read/29025912/variable-outcome-and-methylation-status-according-to-cebpa-mutant-type-in-double-mutated-acute-myeloid-leukemia-patients-and-the-possible-implications-for-treatment
#20
Dima El-Sharkawi, Duncan Sproul, Christopher G Allen, Andrew Feber, Melissa Wright, Robert K Hills, David C Linch, Rosemary E Gale
Although CEBPA double-mutated (CEBPADM) acute myeloid leukemia is considered to be favorable-risk disease, relapse remains a major cause of treatment failure. Most CEBPADM patients have a classic biallelic mutant combination with an N-terminal mutation leading to production of p30 protein plus a C-terminal loss-of-function in-frame indel mutation (CEBPAClassic-DM), but approximately one-third of cases have one or more non-classic mutations, with diverse combinations reported, and there is little information on the consequences of such mutants...
October 12, 2017: Haematologica
keyword
keyword
1185
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"